Investors Buy Shares of Mednax, Inc (MD) on Weakness

Investors bought shares of Mednax, Inc (NYSE:MD) on weakness during trading hours on Tuesday. $37.81 million flowed into the stock on the tick-up and $17.36 million flowed out of the stock on the tick-down, for a money net flow of $20.45 million into the stock. Of all companies tracked, Mednax had the 25th highest net in-flow for the day. Mednax traded down ($1.27) for the day and closed at $45.71

A number of research firms have commented on MD. Jefferies Group LLC reaffirmed a “hold” rating and set a $58.00 target price on shares of Mednax in a report on Wednesday, April 26th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. Bank of America Corporation lowered shares of Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $55.00 to $68.00 in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $63.00.

The stock has a market capitalization of $3.90 billion, a P/E ratio of 13.46 and a beta of 0.40. The stock’s 50-day moving average is $51.66 and its 200 day moving average is $60.50.

Mednax (NYSE:MD) last posted its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the company posted $1.03 earnings per share. On average, equities research analysts expect that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.

In other Mednax news, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total value of $1,282,985.00. Following the transaction, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the transaction, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. QS Investors LLC raised its position in Mednax by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after buying an additional 12 shares during the period. PNC Financial Services Group Inc. raised its position in Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock worth $632,000 after buying an additional 47 shares during the period. Pacer Advisors Inc. raised its position in Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares during the period. Morgan Dempsey Capital Management LLC raised its position in Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after buying an additional 78 shares during the period. Finally, Bronfman E.L. Rothschild L.P. raised its position in Mednax by 3.0% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,122 shares of the company’s stock worth $217,000 after buying an additional 92 shares during the period.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://rinconhillneighbors.org/2017/08/19/traders-buy-mednax-inc-md-on-weakness-updated-updated.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.